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Abstract 
Background: Proteins that ‘read’ the histone code are central elements in epigenetic control and bromodomains, 
which bind acetyl‑lysine motifs, are increasingly recognized as potential mediators of disease states. Notably, the 
first BET bromodomain‑based therapies have entered clinical trials and there is a broad interest in dissecting the 
therapeutic relevance of other bromodomain‑containing proteins in human disease. Typically, drug development is 
facilitated and expedited by high‑throughput screening, where assays need to be sensitive, robust, cost‑effective and 
scalable. However, for bromodomains, which lack catalytic activity that otherwise can be monitored (using classical 
enzymology), the development of cell‑based, drug‑target engagement assays has been challenging. Consequently, 
cell biochemical assays have lagged behind compared to other protein families (e.g., histone deacetylases and 
methyltransferases).
Results: Here, we present a suite of novel chromatin and histone‑binding assays using AlphaLISA, in situ cell extrac‑
tion and fluorescence‑based, high‑content imaging. First, using TRIM24 as an example, the homogenous, bead‑based 
AlphaScreen technology was modified from a biochemical peptide‑competition assay to measure binding of the 
TRIM24 bromodomain to endogenous histone H3 in cells (AlphaLISA). Second, a target agnostic, high‑throughput 
imaging platform was developed to quantify the ability of chemical probes to dissociate endogenous proteins from 
chromatin/nuclear structures. While overall nuclear morphology is maintained, the procedure extracts soluble, non‑
chromatin‑bound proteins from cells with drug‑target displacement visualized by immunofluorescence (IF) or micros‑
copy of fluorescent proteins. Pharmacological evaluation of these assays cross‑validated their utility, sensitivity and 
robustness. Finally, using genetic and pharmacological approaches, we dissect domain contribution of TRIM24, BRD4, 
ATAD2 and SMARCA2 to chromatin binding illustrating the versatility/utility of the in situ cell extraction platform.
Conclusions: In summary, we have developed two novel complementary and cell‑based drug‑target engagement 
assays, expanding the repertoire of pharmacodynamic assays for bromodomain tool compound development. These 
assays have been validated through a successful TRIM24 bromodomain inhibitor program, where a micromolar lead 
molecule (IACS‑6558) was optimized using cell‑based assays to yield the first single‑digit nanomolar TRIM24 inhibitor 
(IACS‑9571). Altogether, the assay platforms described herein are poised to accelerate the discovery and development 
of novel chemical probes to deliver on the promise of epigenetic‑based therapies.
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Background
Histone acetylation is a well-characterized modification 
that is regulated by opposing activities of histone acetyl-
transferases (HATs) and histone deacetylases (HDACs). 
The histone code hypothesis, originally proposed a dec-
ade ago [1], suggests that specific combinations of his-
tone post-translational modifications (PTMs) constitute 
an epigenetic marking system that determines distinct 
transcriptional and functional outputs of eukaryotic 
genomes. These epigenetic marks can be ‘read’ by pro-
teins that specifically bind to single or combined histone 
PTMs [2].
In humans, recognition of acetyl lysine is accomplished 
by a conserved family of 61 bromodomains encoded by 
42 human genes [3]. Many bromodomain-containing 
proteins have additional regulatory and protein–protein 
interaction domains, which contribute in a combinato-
rial manner to highly specialized functions as transcrip-
tional regulators, chromatin remodelers, splicing factors, 
scaffolding proteins and signal transducers. For example, 
some bromodomains are flanked by catalytic domains 
with ATPase, methyltransferase or acetyltransferase 
enzymatic activity but, in most cases, the functional con-
tribution of bromodomains to the biological activity of 
multi-domain proteins remains unknown [3]. Neverthe-
less, with the first BET bromodomain-based therapies in 
clinical trials showing early signs of efficacy, bromodo-
mains are increasingly recognized as mediators of a wide 
range of disease states and, as such, offer attractive candi-
date therapeutic targets [4].
A key step in the drug discovery process is optimiza-
tion of chemical probes using relevant biochemical and 
cellular assays. Typically, the identification of small-
molecule inhibitors is facilitated and expedited by high-
throughput screening (HTS), where assays need to be 
sensitive, robust, cost-effective and scalable [5]. For 
bromodomains, which lack catalytic activity that other-
wise can be monitored (i.e., using classical enzymology), 
the development of cell-based, drug-target engagement 
assays to support probe development has been challeng-
ing. Proximity-based, resonance energy transfer methods 
(where excited-state energy is transferred from one fluo-
rophore to another) have been widely used to detect pro-
tein–protein interactions in living cells [6], and recently, 
a bioluminescence-based assay (nanoBRET) was devel-
oped using cells expressing luciferase-tagged BRD4 and 
histone H3.3-HT fusion proteins [7]. Likewise, a time-
resolved fluorescence resonance energy (TR-FRET) 
assay has been developed to quantify the interaction of 
transfected BRD4 bromodomain with chemical inhibi-
tors inside cells based on ligand-induced protein stabili-
zation [8]. Historically, however, Fluorescence Recovery 
After Photobleaching (FRAP), which requires confocal 
laser scanning microscopy, has been the most widely 
used assay to determine differences in diffusion rates of 
GFP-tagged bromodomains in the presence or absence of 
small-molecule inhibitors [9]. As described, the cellular 
FRAP assay can detect whether a compound can modu-
late chromatin binding (i.e., the diffusion rate) of trans-
fected GFP-tagged bromodomains, but the FRAP assay 
lacks sufficient sensitivity or throughput to rank-order 
inhibitor potency to drive aggressive lead optimization 
programs. This is in contrast to the histone methyl-
transferase field where multiple homogenous, cell-based 
assays are commercially available using AlphaLISA and 
LanthaScreen technologies, as exemplified by Histone 
tri-methylation (H3K27Me3) kits for the development 
of EZH2 inhibitors [10]. Hence, what is needed for bro-
modomain drug discovery is a convenient, cell-based 
method, suitable for HTS, to measure displacement of 
bromodomains from histones or chromatin.
Here, we describe three bromodomain-binding assays, 
using TRIM24 as an example: one in vitro assay that meas-
ures histone peptide (H3K23Ac) binding to TRIM24 and 
two novel cell-based assays that capture TRIM24 binding 
to either endogenous histone H3 or chromatin/nuclear 
structures in cells. The two cellular assays use orthogonal 
detection methods: amplified luminescent proximity bead-
based technology (AlphaLISA) and fluorescent high-con-
tent imaging, respectively. To our knowledge, these are the 
first quantitative, high-throughput methods for the direct 
visualization of bromodomain–histone binding and inhib-
itor-mediated disruption of binding in cells, miniaturized 
to 384-well plate format with excellent plate statistics and 
assay performance. The in  situ cell extraction protocol, 
coupled with high-content IF imaging, is target agnostic 
and can in principle be used to quantify the displacement 
of any protein of interest from chromatin in any target cell, 
thereby expanding the repertoire of epigenetic HTS assays 
for chemical probe discovery.
Results and discussion
Considerations when identifying peptide ligands 
for bromodomain assay development
Prior to embarking on the development of cell-based bro-
modomain assays, we first established biochemical assays 
Keywords: Bromodomain–histone‑binding assays, Chromatin drug‑target displacement, AlphaLISA, AlphaScreen, In 
situ cell extraction, TRIM24, Bromodomain inhibitor, IACS‑9571, IACS‑6558
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to identify small-molecule inhibitors of recombinant 
purified bromodomains. The identification of sufficiently 
tight-binding peptides is usually a key challenge when 
developing in  vitro bromodomain-binding assays, as 
illustrated by our work on ATAD2 [11], where a combi-
nation of crystallography, empirical screening of peptides 
and mutagenesis was required to identify an active-site 
ligand (H4K5Ac) suitable for small-molecule HTS (Addi-
tional file  1: Figure S1). Dissociation constants between 
bromodomains and synthetic peptides are typically in 
the micromolar or millimolar range [12]; however, since 
most bromodomains are present in large multi-domain 
proteins, it is appreciated that bromodomains often act in 
concert with other regulatory domains. For example, the 
adjoining plant homeodomain (PHD) and bromodomain 
in TRIM24 function as a single unit in combinatorial rec-
ognition of unmodified H3K4 and H3K23Ac within the 
same histone tail [13]. Notably, this domain architec-
ture confers enhanced avidity towards the correspond-
ing histone H3 peptide (KD of 96  nM) as measured by 
ITC [13]. Here, we expressed and purified recombinant 
PHD-bromodomain (His-TRIM24), which yielded a KD 
of 187 nM (Fig. 1a) for a biotinylated H3K23Ac peptide 
(N-terminal residues 1–33 of histone H3) using biolayer 
interferometry. Hence, we conclude that the biotin tag on 
the synthetic H3K23Ac peptide minimally interferes with 
TRIM24 bromodomain binding, highlighting the utility 
of this labeled peptide for development of a bromodo-
main/peptide-displacement assay.
Development of a TRIM24/peptide‑displacement 
AlphaScreen assay
To explore the development of an HTS-friendly and 
homogenous ligand binding assay, purified recombi-
nant wild-type (WT) and mutant (N980A) His-TRIM24 
were incubated with the biotinylated H3K23Ac peptide, 
followed by sequential addition of Streptavidin-coated 
donor beads and Ni–NTA acceptor beads. Clearly, simi-
lar to AlphaScreen assays for BRD4 and ATAD2 [11, 12], 
formation of the TRIM24/H3-peptide complex brought 
the donor and acceptor beads into proximity of each 
other with laser irradiation of the donor beads (680 nm) 
resulting in chemiluminescent emission (570  nm) of 
nearby acceptor beads (Fig. 1b). With the H3K23Ac pep-
tide in excess (1 µM), the AlphaSignal for TRIM24 WT 
was dosage proportional up to 30 nM affording a signal 
to background (S/B) of  >250, with no detectable signal 
over background for the bromodomain-binding-defi-
cient mutant (N980A) harboring a classical mutation of 
a conserved asparagine required for coordination and 
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Fig. 1 Characterization of the H3K23Ac peptide ligand for the bio‑
chemical TRIM24 AlphaScreen assay development. a Binding affinity 
(KD) of the His‑TRIM24‑PB/H3K23Ac‑peptide interaction calculated 
from kinetic fitting of the association and dissociation profiles meas‑
ured by biolayer interferometry. b AlphaScreen signal to background 
(S/B) for His‑TRIM24‑PB binding to the biotinylated‑H3K23Ac peptide 
(1 µM) using the indicated amounts of wild‑type (WT) and bromo‑
domain mutant (N980A) protein. c AlphaScreen assay optimization 
using a matrix of TRIM24 protein and peptide (i.e., twofold dilution 
series starting from 20 to 60 nM, respectively). The Alpha Signal (S/B) 
is the average of 2 independent 384‑well plates highlighting condi‑
tions (red box) selected for the final assay protocol (Additional file 1: 
Table S1). d AlphaScreen peptide competition and dose–response 
validation. Non‑biotinylated H3K23Ac peptide was titrated into a 
solution of His‑TRIM24‑PB (5 nM) and biotinylated‑H3K23Ac peptide 
(15 nM) with IC50 curves shown from 6 independent plates
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handling steps, the final assay conditions selected were 
5  nM TRIM24 and 15  nM peptide, which provided an 
assay window with a S/B ratio of 432 (Fig. 1c; Additional 
file 1: Table S1). Finally, given the absence of small-mol-
ecule TRIM24 inhibitors at the time of assay develop-
ment, we titrated a non-biotinylated H3K23Ac peptide 
into the assay and confirmed dose-dependent competi-
tion against the biotinylated sister peptide measuring an 
IC50 of 180 nM (Fig. 1d). Collectively, these experiments 
validated the TRIM24 AlphaScreen assay for chemical 
library screening [11, 14] and we embarked on devel-
oping a suite of cellular assays to follow-up on the HTS 
campaign.
Characterization of TRIM24 bromodomain binding 
to histone H3 in cells
To develop cellular TRIM24 binding assays for drug-
target engagement studies, we generated stable HeLa 
cell lines expressing full-length TRIM24 (TRIM24-FL) 
or isolated PHD-bromodomain (TRIM24-PB) as shown 
by Western blotting (Fig. 2a). Both constructs were dual 
epitope tagged with FLAG at the N-terminus and V5 at 
the C-terminus. In response to HDAC inhibitor treat-
ment with Trichostatin A (TSA) or Suberoylanilide 
Hydroxamic Acid (SAHA), the cellular histone H3K23Ac 
mark that TRIM24 bromodomain binds becomes 
hyperacetylated (Fig.  2a, b). Importantly, anti-FLAG 
immunoprecipitation (IP) of TRIM24 was able to co-
immunoprecipitate (Co-IP) histone H3 from cells. How-
ever, in contrast to IP of endogenous full-length TRIM24 
(Fig. 2b), the isolated PHD-bromodomain (TRIM24-PB) 
formed a detectable immune complex with endogenous 
histone H3 only when cells were pretreated with HDAC 
inhibitor to increase overall histone acetylation lev-
els (Fig.  2c). Notably, compared to the input lysate, the 
immunoprecipitated histone H3 showed minimal H3K4 
methylation levels relative to H3K23 acetylation (Fig. 2c), 
consistent with the specific TRIM24-PB recognition 
motif defined by X-ray crystallography (i.e., H3K4 meth-
ylation of the H3K23Ac(1–33) peptide reduces its bind-
ing affinity to the TRIM24 PHD-bromodomain through 
steric hindrance) [13]. Interestingly, HDAC inhibitors are 
known to induce H3K4 methylation [15, 16], and since 
this mark is tightly associated with promoters of active 
genes [17], our Co-IP studies suggest that TRIM24 is not 
recruited to this subset of transcriptional active promot-
ers [18].
To further characterize recruitment of TRIM24-PB 
to acetylated histone H3 in intact cells, we next applied 
a proximity ligation assay (PLA) [19] to visualize the 
SAHA-induced binding using a pair of anti-V5 and anti-
histone H3 antibodies (Fig.  2d; Additional file  1: Fig-
ure S2). Indeed, SAHA treatment (2  h, 5  µM) led to a 
greater than threefold increase in the TRIM24/H3 PLA 
signal (Fig.  2d—blue dots), whereas mean nuclei levels 
of TRIM24 did not change, as measured by Alexa-con-
jugated secondary antibodies (Additional file  1: Figure 
S2c). Altogether, the TRIM24 co-IP and PLA co-locali-
zation studies suggested that the engineered HeLa cells 
are a suitable model system for development of cellular 
bromodomain–histone-binding assays to support small-
molecule drug discovery.
Development of cellular TRIM24‑histone AlphaLISA 
binding assay: selection of cell line
To identify optimal conditions for TRIM24 bind-
ing to endogenous histone H3 in cells, we next con-
ducted SAHA time– and dose–response studies using 
anti-H3K23Ac immunostaining (Fig.  2e—yellow). We 
observed that treatment with 3 µM SAHA for 2 h is suf-
ficient to drive maximal H3K23 acetylation in both HeLa 
control and TRIM24-PB expressing cells (Fig.  2f—left 
graph). Prior to paraformaldehyde fixation, we intro-
duced an in situ cell extraction step, similar to methods 
(See figure on next page.)
Fig. 2 Characterization of engineered HeLa cells expressing TRIM24 full‑length or isolated PHD‑bromodomain. a Western blot analysis of stable 
HeLa cell lines expressing either vector control (−) or dual‑tagged (FLAG‑TRIM24‑V5) full‑length (FL) or isolated PHD‑bromodomain (PB). Lysate 
from cells treated with Suberoylanilide Hydroxamic Acid (SAHA) for 2 h (2 µM) or vehicle control (DMSO) were probed with the indicated antibod‑
ies confirming SAHA‑induced acetylation of H3K23. b Immunoprecipitation of endogenous full‑length TRIM24 (using anti‑TRIM24 antibody) under 
non‑treated (DMSO) and SAHA‑treated (2 µM, 2 h) conditions. c Immunoprecipitation of the TRIM24 PHD‑bromodomain (using anti‑FLAG beads) 
and looking at co‑immunoprecipitated histone H3 in TRIM24‑PB cells non‑treated or treated (2 µM, 2 h) with either Trichostatin A (TSA) or (SAHA). 
d Proximity ligation assay (PLA) of TRIM24‑PB cells using the goat anti‑V5 (i.e., TRIM24‑PB) and mouse anti‑histone H3 antibody pair, showing an 
increase in co‑localization of TRIM24 with histone H3 in response to SAHA treatment (2 µM, 2 h). The increase in proximity of the two proteins 
(number of blue PLA dots) is quantified in Additional file 1: Figure S2. e Representative IF images of TRIM24‑PB cells following SAHA treatment (2 µM, 
2 h) showing acetylation of histone H3K23 (yellow) and increased chromatin binding of TRIM24‑PB (red) with Hoechst nuclear staining (blue) serving 
as a control for the in situ cell extraction procedure. f SAHA dose–response and time‑course studies. Left Graph IF quantification (Arbitrary Units) of 
H3K23Ac in Hela control and TRIM24‑PB cells upon SAHA treatment (2 h). Right Graph IF quantification (average IF signal per nucleus for TRIM24‑PB 
and H3K23Ac as percent of the non‑SAHA‑treated control (PoC)) under in situ cell extraction (+) and non‑extraction (−) conditions. g Schematic 
diagram for measuring the dual‑tagged TRIM24 protein in cell lysates (Top) showing AlphaLISA results for HeLa cells (Parental, TRIM24‑FL and 
TRIM24‑PB) using anti‑FLAG donor and anti‑V5 acceptor beads (Middle) compared to immunoblotting (Bottom)
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previously applied to yeast cells [20, 21], to remove solu-
ble, non-chromatin-bound proteins. Under these condi-
tions, we observed that TRIM24-PB became resistant to 
detergent extraction, indicating that the PHD-Bromo-
domain bound more tightly to chromatin and/or related 
nuclear structures with SAHA treatment (Fig.  2e—red) 
while total cell number (Hoechst) remained unchanged 
(Fig.  2e—blue). Notably, the chromatin binding of 
TRIM24-PB occurred concomitantly with SAHA-
induced acetylation of H3K23Ac (Fig.  2f—right graph), 
consistent with a direct TRIM24 protein–histone 
interaction.
Finally, to explore the feasibility of a homogenous, 
proximity-based AlphaLISA assay, we next incubated 
HeLa cell lysates (parental, TRIM24-FL or TRIM24-PB) 
with anti-FLAG and anti-V5 antibodies conjugated to 
acceptor and donor beads, respectively, as detection rea-
gents. As illustrated in the cartoon (Fig.  2g—top), this 
allowed us to evaluate the intensity (and specificity) of 
the AlphaLISA signal, leveraging the dual-tagged (FLAG 
and V5) TRIM24 protein as a best-case scenario for assay 
sensitivity. Clearly, the AlphaLISA was sensitive enough 
to detect expression of full-length, tagged TRIM24, 
which was overexpressed two- to threefold above endog-
enous levels (Fig. 2g—middle). In comparison, the HeLa 
cell line expressing TRIM24-PB produced an AlphaLISA 
S/B of 220, consistent with the higher expression level 
of the smaller PHD-bromodomain construct evident 
from the anti-TRIM24 Western blot (Fig.  2g—bottom). 
Robust detection of dual-tagged TRIM24-PB (S/B > 200) 
in lysates obtainable from a single well (i.e., 10,000 cells 
in a 96-well plate format) was encouraging as it implies, 
at least theoretically, the ability to detect TRIM24-PB in 
complex with endogenous histone H3 in a high-through-
put format. Here, motivated by a desire to have a high 
AlphaLISA signal for small-molecule library screening, 
we hence proceeded with the HeLa TRIM24-PB cell line 
for HTS assay development.
Development of a cellular TRIM24‑histone AlphaLISA 
assay: optimization of cell lysis and histone extraction 
buffers to preserve bromodomain/histone interactions
Using the depicted AlphaLISA reagents (Fig. 3a), we next 
explored whether we could detect a TRIM24/histone H3 
complex in cell lysates. Specifically, either V5- or FLAG-
conjugated acceptor beads were paired with a bioti-
nylated anti-histone H3 antibody, followed by addition 
of Streptavidin-coated donor beads and signal acquisi-
tion (Fig. 3b, c). Not surprisingly, the default (i.e., manu-
facturer recommended) cell lysis and histone extraction 
protocol for the anti-H3 AlphaLISA antibody [10], which 
have been optimized to capture histone H3 and meas-
ure levels of H3K27 tri-methylation, which is a covalent 
modification, were too harsh to maintain specific bro-
modomain–histone protein–protein interaction. Hence, 
we explored a range of different lysis conditions by incu-
bating V5/H3 (Fig. 3b) and FLAG/H3 (Fig. 3c) antibody 
pairs under less stringent conditions, initially diluting the 
Histone Extraction Buffer up to tenfold in water (1:1, 1:2, 
1:5 and 1:10). Using the lysis buffer defined in Additional 
file  1: Table S2, a significant immune complex between 
TRIM24-PB and endogenous histone H3 emerged when 
the Histone Extraction Buffer was diluted 1:5 or more 
(Fig. 3b, c). Specifically, a 50-fold assay window (S/B) was 
found for FLAG-acceptor and Streptavidin-donor beads, 
using a 1:10 dilution of the histone extraction buffer 
(Fig. 3c), compared to 14-fold (S/B) for V5-acceptor and 
Streptavidin-donor beads (Fig. 3b). Replacing the Histone 
Extraction Buffer entirely with water reduced the S/B 
from 50 to 20 for FLAG-acceptor beads (Fig. 3c). Of note, 
we also explored enzymatic means of digesting chroma-
tin (i.e., using micrococcal nucleases) and varied the ionic 
strength and pH of the lysis buffer to see whether these 
conditions could further help expose the epitope recog-
nized by the biotinylated H3 antibody; however, none 
of these efforts further improved the S/B to reach levels 
above 50. Therefore, we proceeded with assay develop-
ment as described below.
Optimization (384‑well plate) and pharmacological 
validation of the AlphaLISA assay
For the final AlphaLISA assay optimization, we titrated 
the amount of biotinylated H3-antibody (keeping FLAG-
acceptor and Streptavidin-donor beads constant) and 
observed the typical ‘hook’ effect, a well-understood phe-
nomenon for saturable bimolecular detection systems 
[22], at 0.57  nM histone H3 antibody (Fig.  3d). Hence, 
we selected 0.5 nM as the optimal H3 antibody concen-
tration and repeated the SAHA dose- and time-course 
studies (Fig.  2e), now detecting the formation of the 
TRIM24/histone complex directly in cells processed in 
384-well tissue culture plates (Fig. 3e, f ). The kinetics of 
the TRIM24/histone-H3 complex formation as measured 
by AlphaLISA was consistent with that obtained by IF 
(Fig. 2e), validating the final protocol for our small-mole-
cule drug discovery program (Additional file 1: Table S2).
Titration curves for IACS-6558, a TRIM24 bromo-
domain inhibitor (TRIM24i) identified during our 
structure-guided drug discovery program [14] are high-
lighted to document the sensitivity and reproducibility 
of the AlphaLISA assay affording an IC50 of 1.5 ± 0.3 µM 
(Fig. 3g). The assay performance and plate statistics (sam-
pled from 26 plates; 384-well format) are clearly accepta-
ble for a cell-based assay (S/B of 30; S/N of 11; Z′ of 0.67) 
[23]. Moreover, as part of the lead optimization process, 
we observed a strong correlation (R2  =  0.92) between 
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affinities for chemical matter tested in both the bio-
chemical TRIM24/histone-peptide-displacement assay 
(AlphaScreen) and the cellular TRIM24/histone-binding 
assay (AlphaLISA) (Fig.  3h). Ultimately, combined with 
molecular structure-guided insights (i.e., X-ray crystal-
lography), this enabled us to develop drug-like probes 
with minimal cell-shift and single-digit nanomolar activ-
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Fig. 3 Cellular AlphaLISA assay development to detect bromodomain–histone H3 interactions in HTS format. a Schematic diagram for quantify‑
ing the association of TRIM24 and histone H3 in cells using AlphaLISA. Streptavidin‑coated donor beads capture the immune complex between 
the biotinylated anti‑H3 antibody and histone H3. Acceptor beads (directly conjugated to either anti‑FLAG or anti‑V5 antibodies) captures TRIM24. 
If a test agent displaces TRIM24 from histone H3, it will lead to decreased Alpha Signal. b, c Stringency of histone extraction evaluated for HeLa 
TRIM24‑PB cells pretreated with either DMSO or SAHA (5 µM, 2 h) using the indicated AlphaLISA acceptor beads (V5 or FLAG) and a dilution series 
of the histone extraction buffer. d Titration of the anti‑histone H3 antibody with FLAG‑acceptor beads (5 mg/mL). e SAHA time‑course (5 µM) and f 
dose–response (2 h) studies for TRIM24‑PB HeLa cells plated in 384‑well plates and subjected to the AlphaLISA protocol (Additional file 1: Table S2). 
g Dose–response curves for cells treated with IACS‑6558, the depicted small‑molecule TRIM24 bromodomain inhibitor (TRIM24i). Inhibitor affinity 
(EC50) is shown as percent binding relative to control (DMSO) from 6 independent experiments. h Correlation plot between biochemical AlphaS‑
creen (IC50) and cellular AlphaLISA (EC50) values for 273 compounds evaluated during our TRIM24 bromodomain drug discovery program [14]
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In situ cell extraction as an orthogonal approach to study 
bromodomain/chromatin binding
Chromatin binding of proteins has been studied using 
various biochemical- and fluorescence-based imaging 
techniques in both fixed and live cells. Specifically, in situ 
cell extraction techniques, which remove proteins not 
bound to nuclear structures, have been used to study 
chromatin binding of individual proteins involved in 
chromatin remodeling, cell cycle and DNA repair [24]. 
Our observation that TRIM24 protein levels in the non-
soluble, nuclear fraction of cells increased concomitantly 
with SAHA-induced acetylation (Fig. 3d) suggested that 
this simple detergent extraction and fixation protocol 
(Fig. 4a) could be developed into an orthogonal and tar-
get agnostic chromatin-binding assay. In principle, such 
assay would be universally applicable across the bromo-
domain protein family and potentially other chromatin-
associated drug targets.
To this end, we first titrated three reference BET-
family bromodomain inhibitors (JQ1 [25], I-BET 151 
[26, 27] and RVX-208 [28] using HeLa cells expressing 
FLAG-tagged BRD4 cultured in 96-well plates (Fig. 4b). 
Strikingly, using two-color staining, we found that JQ1 
and I-BET 151 potently displaced BRD4 (green) from 
chromatin, while the IF signal for histone H3 (red) was 
unaffected by inhibitor treatment (Fig. 4b, c). Moreover, 
BRD4 was displaced from chromatin within 5  min of 
inhibitor treatment (Additional file 1: Figure S3), consist-
ent with the rapid displacement measured by FRAP [9]. 
As such, these data support a direct pharmacological 
effect on binding, rather than a displacement due to sec-
ondary drug-induced transcriptional response.
For quantitative image analysis of the drug response 
(Fig. 4d), we developed a protocol that relied on cell seg-
mentation and gating, based on Hoechst staining fol-
lowed by the measurement of nuclear IF intensity for 
BRD4 and H3 (Fig. 4e). Our automated, script-based pro-
tocol, allowed rapid acquisition of EC50 values using only 
a small fraction (~10 %) of the cells available in a 96-well 
plate. Hence, we miniaturized the assay to 384-well for-
mat further increasing throughput and reducing reagent 
costs (Additional file 1: Figure S4). Moreover, the in situ 
cell extraction assay for BRD4 was exquisitely sensitive 
and appeared to distinguish between even small intrin-
sic differences in potency between JQ1 and I-BET 151 
(Cell IC50 of 132 nM and 86 nM, respectively, compared 
to BromoScan Kd values of 21 and 10  nM obtained in 
parallel at DiscoveRx for the recombinant purified pro-
teins [29]). The wide dynamic range and sensitivity of the 
in situ cell extraction assay was further evident from the 
partial displacement of BRD4 from chromatin by RVX-
208, a compound that selectively binds to the second 
bromodomain of BET proteins [28, 30]. Interestingly, 
the BRD4 overexpressing cells do not require SAHA pre-
treatment to measure drug-target displacement, as the 
FLAG-tagged BRD4 protein is chromatin bound in the 
basal, non-hyperacetylated state.
Simplified and HTS‑friendly GFP‑version of the in situ cell 
extraction assays
In an HTS setting, we further simplified the in  situ cell 
extraction procedure by replacing the indirect IF step 
(e.g., anti-FLAG) with cells engineered to express fluo-
rescent moieties (e.g., GFP) fused to the protein target of 
interest (Additional file 1: Figure S5). In this format, the 
assay has minimal time and reagent costs associated with 
HTS operation, since no further liquid handling or pro-
cessing steps are needed after detergent extraction and 
fixation. For example, for the TRIM24 inhibitor, dose–
response curves using HeLa cells expressing GFP-tagged 
TRIM24 and the in situ cell extraction procedure yielded 
EC50 values comparable to the AlphaLISA assay, record-
ing 2.3  µM (Additional file  1: Figure S5B) and 1.3  µM 
(Fig. 3g), respectively. This is particularly noteworthy for 
two orthogonal assays that monitor either the displace-
ment of TRIM24 from chromatin/nuclear structures or 
directly measure TRIM24/histone-H3 dissociation in 
cells. Moreover, we also note that the assay is robust to 
the duration of the in situ cell extraction step (4–13 min) 
affording very similar IC50 values (Additional file 1: Fig-
ure S6), and we chose a 10-min incubation step for test 
compounds as the final protocol (Additional file 1: Table 
S3).
Pharmacodynamic evaluation of endogenous proteins 
using in situ cell extraction
In an effort to measure pharmacodynamic changes in 
the association of endogenous TRIM24 with chromatin 
in tumor cells, we next validated the utility of an anti-
TRIM24 antibody in HeLa TRIM24-PB (Fig.  5a, b) and 
non-transfected cancer cells (Fig. 5c). In HeLa cells, the 
anti-TRIM24 antibody provided a smaller assay window 
for the SAHA-induced TRIM24-PB chromatin binding 
(twofold), compared to the anti-FLAG antibody (five-
fold), but both antibodies recorded similar dose-depend-
ent TRIM24 inhibitor responses reducing the IF signal 
to baseline (i.e., the level observed without SAHA treat-
ment) (Fig.  5a, b). Together with siRNA knock-down 
(data not shown), these findings confirmed the specific-
ity and sensitivity of the TRIM24 antibody for IF stud-
ies, eliminating the need for an engineered epitope tag. 
Hence, we qualified the anti-TRIM24 antibody in cancer 
cells as shown for the ovarian OV90 cell line using a simi-
lar treatment matrix (Fig.  5c). We found that the mean 
IF nuclei intensity did not change in response to SAHA 
treatment or following in  situ cell extraction indicating 
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Fig. 4 Pharmacological proof‑of‑concept for the in situ cell extraction methodology using reference BET bromodomain inhibitors. a Outline of the 
in situ cell extraction procedure. b 96‑well plate view for BET bromodomain inhibitor treatment of HeLa cells expressing FLAG‑tagged full‑length 
BRD4. Cells were subjected to in situ cell extraction and two‑color IF staining for TRIM24 (green) and histone H3 (red). The plate layout shows serial 
dilution of 3 BET inhibitors (JQ1, RVX‑280 and I‑BET) including wells with DMSO and secondary antibody controls. c Magnified IF images show 
decrease of BRD4 staining upon JQ‑1 treatment (10 µM), while histone H3 (red) and Hoechst staining remains unchanged. d Quantification of 
drug dose responses based on IF image analysis. e Image analysis sequence using Harmony software. Left panel cell segmentation and gating 
strategy based on Hoechst (blue) staining eliminating cells of inappropriate morphology (red on the second image). Right panel the same cells with 
co‑staining for BRD4 (green) and H3 (red). The mean intensity of the BRD4 signal was measured per nucleus and the average nucleus intensity was 
calculated from about 1000 gated cells (i.e., excluding the masked white cells on the fourth image)
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Fig. 5 Development of in situ cell extraction to monitor the displacement of endogenous TRIM24 from chromatin in cells. a Representative IF 
images of HeLa TRIM24‑PB cells using either anti‑FLAG (red) or anti‑TRIM24 (green) antibodies under in situ cell extraction (+) and non‑extraction 
(−) conditions and in the presence or absence of IACS‑6558, a TRIM24 inhibitor. b Quantification of the fraction of chromatin‑bound TRIM24 upon 
inhibitor treatment (2 h) of the above HeLa TRIM24‑PB cells. c OV90 cancer cells treated as above using the same anti‑TRIM24 antibody to detect 
endogenous TRIM24 expression and displacement upon TRIM24 inhibitor (IACS‑6558) treatment. d Representative images (HeLa TRIM24‑PB) show‑
ing rapid displacement of TRIM24 (red) from chromatin in response to TRIM24 inhibitor (IACS‑6558) treatment. e Quantification of the inhibitor‑
induced displacement of TRIM24‑PB from chromatin in HeLa (left graph) and non‑transfected OV90 cells looking at endogenous TRIM24 (right 
graph)
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that endogenous TRIM24 is firmly bound to chromatin 
under physiological conditions (i.e., present in the non-
soluble nuclear fraction of cells). However, the chromatin 
binding of endogenous TRIM24 was readily reduced in 
response to pharmacological TRIM24 inhibition (IACS-
6558), which clearly is a more relevant PD biomarker 
assay compared to the displacement of exogenously 
expressed PhD-bromodomain. Furthermore, the rapid 
displacement of both endogenous TRIM24 and TRIM24-
PB from chromatin, which occurs within 5 min of inhibi-
tor treatment (Fig.  5e), resembles the kinetics observed 
for displacement of BRD4 by the JQ1 bromodomain 
inhibitor (Additional file 1: Figure S3). Altogether, these 
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Fig. 6 Pharmacological cross‑validation of cellular histone and chromatin‑binding assays with the TRIM24 biochemical AlphaScreen assay. a 
Merged IF images of two‑color staining of OV90 cells following in situ cell extraction showing TRIM24 inhibitor‑mediated displacement of endoge‑
nous TRIM24 (green) from chromatin while leaving histone H3 (red) protein levels unchanged (IACS‑6558, 10 µM, 2 h). b Dose–response curves for a 
dozen TRIM24 inhibitors (1 h, no SAHA treatment) in OV90 cells using in situ cell extraction and IF detection/quantification. c EC50 values calculated 
from the above drug titration studies in OV90 cells (percent inhibition relative to DMSO control wells) were correlated with values obtained from 
the biochemical AlphaScreen and the cellular AlphaLISA assays
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potential universal assay platform for studying the phar-
macological effects of compounds on chromatin-associ-
ated drug targets.
Cross‑validation of cellular and biochemical assays using a 
panel of TRIM24 inhibitors
Finally, as part of our ongoing lead optimization, we next 
selected 18 random inhibitors, which displayed a 3-log 
range in potency in cellular AlphaLISA assays, and eval-
uated their activity in OV90 cells using the in  situ cell 
extraction assay (Fig.  6). Upon measuring their potency 
against endogenous TRIM24 in OV90 cells (Fig. 6b), we 
next correlated the EC50 values with those obtained from 
the cellular TRIM24/histone H3 binding assay (AlphaL-
ISA) as well as the biochemical AlphaScreen peptide-
displacement assay (Fig.  6c). Importantly, we observed 
correlation coefficients (R2  >  0.6) for these complemen-
tary assays, further supporting the use of the in situ cell 
extraction protocol for endogenous drug-target engage-
ment assessment.
In situ cell extraction as a platform to dissect the 
contribution of individual domains to chromatin binding
The bromodomain drug discovery field is complicated by 
the fact that many of these proteins contain multiple con-
served domains, involved in chromatin binding and pro-
tein–protein interactions, and by the fact these proteins 
are frequently part of large protein complexes (Fig.  7a). 
Therefore, we next wanted to explore whether the in situ 
cell extraction technique could be used as a general strat-
egy to decipher the contribution of individual bromo-
domains to chromatin biology. To this end, we focused 
on TRIM24, SMARCA2 and ATAD2 as they represent 
prominent candidates for anti-cancer drug discovery [13, 
31–34]. Focusing on full-length proteins, we expressed 
FLAG-tagged wild-type (WT) and bromodomain-bind-
ing-deficient mutant (BRD mut) constructs in cells and 
subjected these to the in situ cell extraction protocol fol-
lowed by IF quantification (Fig. 7b, c).
Consistent with pharmacological TRIM24 inhibitor 
studies, the bromodomain mutant form of full-length 
TRIM24, displayed a drastically reduced affinity for 
chromatin, compared to the WT TRIM24 counterpart 
(Fig. 7c; black and green bars, respectively). As such, this 
mutational study confirmed the essential role of an intact 
bromodomain in the ability of TRIM24 to bind chroma-
tin in cells. For SMARCA2, about 30 % of the ectopically 
expressed full-length protein was present (i.e., chromatin 
bound) following the in situ cell extraction step compared 
to the non-extracted IF signal, but the bromodomain 
mutation (BRD mut) did not significantly alter this level. 
The observation that the SMARCA2 bromodomain is not 
required for chromatin binding is also consistent with 
pharmacological inhibitor studies using the SMARCA2 
chemical probe PFI-3 [35]. Likewise, for ATAD2, no sig-
nificant difference in chromatin binding was observed 
between the WT and bromodomain mutant con-
structs (Fig. 7c). However, when we overexpressed vari-
ous mutant forms of ATAD2, we noted that the nuclear 
localization of ATAD2 was significantly altered in cells 
expressing an ATPase dead construct (compared to WT 
and BRD mut constructs), as exemplified by studies in 
human mammary epithelial cells (hMECs) (Fig.  7d). In 
these cells, chromatin binding of ATAD2 was assessed 
under increasingly stringent in  situ cell extraction con-
ditions ranging from 0 to 500 mM NaCl (Fig. 7e). Con-
trary to the ATAD2 WT and BRD mut proteins, which 
displayed similar affinities to each other for chromatin 
structures, the ATPase dead protein resided primarily in 
the nuclear soluble fraction, removed by the in  situ cell 
extraction procedure, revealing a dependency on func-
tional ATPase activity for chromatin binding and hence 
subnuclear distribution. In conclusion, the in  situ cell 
extraction assay is a powerful cell-based methodology 
to evaluate not only bromodomain inhibition, but also 
to dissect the role/contribution of different domains in 
chromatin binding and to provide critical insights into 
both drug-target discovery and basic science.
Conclusions
Multiple biochemical assays have been utilized to support 
the discovery of small-molecule inhibitors of epigenetic 
(See figure on next page.) 
Fig. 7 In situ cell extraction applied to genetic studies of chromatin binding for candidate drug targets TRIM24, SMARCA2 and ATAD2. a Schematic 
representation of proteins highlighting the multi‑domain nature of select bromodomain‑containing genes. b A functional TRIM24 bromdomain is 
required for chromatin binding. IF images of HeLa cells expressing FLAG‑tagged wild‑type (WT) or bromodomain‑binding‑deficient mutant (BRD 
mut) forms of full‑length TRIM24 under in situ cell extraction (+) and non‑extraction (−) conditions. c Quantification of the indicated FLAG‑tagged 
full‑length proteins (ATAD2, TRIM24 and SMARCA2) in the nuclei of transfected HeLa cells after in situ cell extraction (CSK buffer with 100 mM NaCl) 
for wild‑type (black) and bromodomain mutant (green) proteins (n = 3; similar results observed across different cell lines including HeLa, hMECs and 
A549; data not shown). d Representative IF images of hMECs expressing FLAG‑tagged full‑length (WT) and mutant ATAD2 constructs (BRD mut and 
ATPase dead) followed by IF detection of the ATAD2 transgene (i.e., anti‑FLAG antibody). e Quantification of the nuclear signals for ATAD2 wild‑type 
(WT), BRD mutant and ATPase dead proteins after in situ cell extraction using increasing NaCl stringency. Changing the stringency of the in situ cell 
extraction (0–500 mM NaCl) does not change the relative rank order of their chromatin‑binding affinities
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enzymes, but the development of cellular binding assays 
for protein–protein interactions involving the so-called 
‘reader’ domains has lagged behind. Cellular assays are 
critically important for the identification and optimiza-
tion of potent inhibitors suitable for in vivo pharmacol-
ogy studies and subsequent clinical development. While 
protein stabilization and fluorescence resonance energy 
transfer (FRET) assays have been developed for BRD2/4 
to detect interaction with small-molecule inhibitors in 
engineered cells [7, 8, 36], no universal cell-based drug-
target engagement assays amenable to 384-well HTS for-
mat have been reported to date for bromodomains.
In this manuscript, we describe two new strategies to 
measure the cellular interaction between bromodomain 
and chromatin; namely (1) proximity-based binding 
(AlphaLISA), and (2) in  situ cell extraction and fluores-
cence-based, high-content imaging. Our detailed proto-
cols (Additional file  1: Tables S1, S2 and S3) add to the 
repertoire of epigenetic cellular assays, paving the way 
for the development of novel chemical probes. Because 
protein–protein interactions regulate numerous cellular 
functions that go awry in cancer, the disruption of inter-
actions related to chromatin modifiers and remodeling 
complexes has been a desirable goal for drug discovery in 
cancer as well as other pathological conditions. In prin-
ciple, our novel assays can be applied to any drug target 
that specifically binds to histones or chromatin/nuclear 
structures.
We have applied the in  situ cell extraction platform 
to diverse proteins and have noticed that many bromo-
domains, in isolation from their flanking protein mod-
ules, are often cytoplasmic or, if nuclear, non-chromatin 
bound in the absence of SAHA treatment. Similar obser-
vations have been reported for a FRET bromodomain 
probe [36] and more recently in studies using FRAP 
analysis for a dozen bromodomains [9]. Although we 
find that short-term HDAC inhibitor treatment is a use-
ful ‘trick’ for developing robust bromodomain-binding 
assays in transfected cell lines, it is clear that SAHA treat-
ment, in addition to increasing the H3K23Ac mark, also 
hyper-acetylates other histone- and non-histone-asso-
ciated proteins [37, 38]. Consequently, transfected and 
ectopically expressed bromodomain constructs may be 
recruited to non-physiological binding sites. Supporting 
this notion is our general observation that for full-length 
bromodomain-containing genes, including TRIM24, 
ATAD2 and SMARCA2/4, stable cell lines tend to display 
low levels of overexpression (one- to threefold compared 
to endogenous) and their binding to chromatin is not 
significantly influenced by SAHA treatment compared 
to the expression of truncated, isolated bromodomain 
constructs. As shown for TRIM24-PB, the isolated bro-
modomain fragment expresses well in stable cell lines, 
potentially because it engages protein complexes within 
cells differently as compared to its full-length counterpart 
(Fig. 3). Nevertheless, for cell-based drug-target engage-
ment assays, aiming to identify and guide the selection 
and design of potent, cell-permeable chemical probes, 
the issue of binding aberrant lysine recognition motifs is 
less of a concern. For lead identification and optimization 
processes, sensitivity, robustness, ease of automation and 
low cost are critical in a HTS setting (384-well plate of 
higher), as lead molecules are typically evaluated down-
stream in complementary cellular and functional assays 
looking at disease-relevant phenotypes.
From a drug discovery and proximal PD biomarker 
perspective, the highest value of the in  situ cell extrac-
tion assay, when using antibody-based IF, resides in the 
opportunity to monitor displacement of endogenous full-
length proteins from physiological sites in the nucleus, 
thereby correlating drug-target engagement with anti-
cancer phenotypes (e.g., apoptosis, differentiation and 
migration) in any target cell of interest. Specifically, when 
applied to our TRIM24 drug discovery project, the abil-
ity to monitor displacement of endogenous full-length 
TRIM24 from chromatin in adherent cell line enables 
pivotal PK/PD/efficacy studies to ensure that the com-
pound phenotype (i.e., anti-viability) is not due to off-
target effects, but rather linked to on-target TRIM24 
activity.
Although the ‘low resolution’ histone- and chromatin-
binding assays (i.e., AlphaLisa and in situ cell extraction) 
developed here are well suited for compound screening, 
the ability to map the genome-wide locations of proteins 
and drug targets at ‘high resolution’ is critical for our 
understanding of normal and disease biology. While not 
amenable to high-throughput screening, global analysis 
methods such as ChIP-seq and Chem-seq are impor-
tant approaches to define how target proteins and small-
molecule inhibitors may perturb specific gene expression 
program [39, 40]. In fact, models of the transcriptional 
regulatory circuitry that controls normal and disease 
states in cells have emerged from genome-wide Chip-Seq 
and Chem-Seq data [35, 39–43] and this global analysis 
represents important follow-up assays for small-mole-
cule drug discovery programs targeting transcription fac-
tors, chromatin regulators and other epigenetic proteins.
The truncated TRIM24 PHD-bromodomain sequence 
is predicted to encode two naturally occurring NLS 
motifs within its Carboxy-terminal tail and, interestingly, 
appending NLS sequences to other GFP-tagged pro-
teins have been used to streamline FRAP assay develop-
ment for a dozen bromodomains [9]. We also found that 
addition of a NLS sequence to an isolated GFP-tagged 
SMARCA2 bromodomain construct is necessary for 
developing in  situ cell extraction assay for SMARCA2. 
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Using this assay, we recently characterized a novel bro-
modomain inhibitor, PFI-3, and reported that while 
PFI-3 can displace the isolated GFP-tagged SMARCA2 
bromodomain from chromatin in engineered cells, it 
fails to displace the endogenous full-length SMARCA2 
protein from chromatin [35]. This has significant impli-
cations for small-molecule drug discovery as SMARCA2 
knock-down causes cancer-specific, phenotypic lethality 
in SMARAC4-null lung cancers [31–33], but bromodo-
main inhibition does not phenocopy the effects of RNAi-
mediated target depletion [35]. Hence, we propose that 
the in situ cell extraction assay can be used to prioritize 
and functionally assess the importance of individual bro-
modomains for chromatin complex formation.
Finally, given the absence of pharmacological inhibitors 
for many bromodomain targets, site-directed mutagen-
esis can also be used to rapidly dissect the contribution 
of individual domains to chromatin binding, as illus-
trated here for ATAD2, where the ATPase domain, but 
not the bromodomain, is driving chromatin association. 
Such results can directly inform on drug discovery efforts 
and, in the case of ATAD2, we predict that such endeav-
ors should be directed towards inhibiting the more chal-
lenging ATPase catalytic domain to mimic the reported 
RNAi phenotype [34]. As such, we believe the in situ cell 
extraction platform has significant implications for dis-
secting the role of individual conserved domains, present 
in a diverse family of emerging epigenetic and chroma-
tin-modifying proteins beyond the bromodomain family 
(e.g., Tudor domains [41, 42]). Altogether, the quantita-
tive, cell-based approaches for measuring bromodo-
main–histone and chromatin interactions, presented 
herein, combined with both genetic and emerging phar-
macological tools, are poised to help prioritizing protein 
families for drug discovery and contribute to the delivery 
of novel epigenetic therapies for human diseases.
Methods
Plasmids and chemicals
Bromodomain mutations were made in human TRIM24 
(N980A) using site-directed mutagenesis (QuickChange, 
Agilent Technologies) with related binding-deficient 
mutations in ATAD2 (GeneCopoeia #GC-Z4424) and 
SMARCA2 (GeneCopoeia #GC-Z4424). The ATAD2 
ATPase dead mutations (K473T and E532Q) were as 
described elsewhere [43]. All cDNAs, subcloned into 
lentiviral vectors (pLEX304; AddGene #25890), were 
sequence verified and virus generation, infection and 
generation of stable cell lines were conducted following 
standard procedures. The FLAG-TRIM24-PB construct 
(residues 810–1050) was generated by PCR amplification 
and cloned in-frame with the V5-tag present in pLEX304. 
Unless otherwise noted, all chemicals, including 
Trichostatin A (TSA) and Suberoylanilide Hydroxamic 
Acid (SAHA) were from Sigma-Aldrich. Synthesis of the 
TRIM24 bromodomain inhibitor, IACS-6558, with the 
following IUPAC name N-{1,3-dimethyl-6-[3-(2-methyl-
propoxy)phenoxy]-2-oxo-2,3-dihydro-1H-1,3-benzodia-
zol-5-yl}-1,2-dimethyl-1H-imidazole-4-sulfonamide, and 
IACS-9571, is described elsewhere [14].
Biolayer interferometry and AlphaScreen binding assays
The His-tagged TRIM24 PHD-bromodomain was 
expressed and purified as previously described 
[13]. The H3K23Ac peptide (AnaSpec, CA, USA) 
used for biolayer interferometry (Red-384, Forte-
Bio, CA, USA) and AlphaScreen (Perkin Elmer) was: 
[ARTKQTARKSTGGKAPRKQLATK(ac)AARKSAP 
ATG-YK(Biotin)]. For biolayer interferometry, Streptavi-
din ‘dip-and-read’ biosensors (ForteBio, #18-5019) were 
loaded with the biotinylated-H3K23Ac peptide in Buffer 
A (20 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM TCEP, 
0.005  % Tween-20). The biosensors were then washed 
in Buffer A and transferred into 96-well plates (Greiner 
#655209) containing a 7-point, 1.5-fold serial dilution of 
the TRIM24 protein (starting from a 67 nM solution in 
Buffer A). The KD for the TRIM24/H3K23Ac interaction 
was calculated from the koff/kon values obtained by kinetic 
fitting of the association and dissociation curves using 
the OctetRed software. AlphaScreen assays were con-
ducted in Buffer B (50 mM Hepes pH 7.4, 100 mM NaCL, 
0.1  % BSA, 0.05  % Chaps) using an automated 384-well 
protocol (Additional file  1: Table S1). In brief, from a 
(1.5×) master mixture of TRIM24 protein (7.5 nM) and 
H3K23Ac (22.5  nM), 8 µL was dispensed into 384-well 
OptiPlates and incubated with 4 µL of test compound 
(or DMSO control) for 1  h at room temperature (RT). 
Streptavidin-donor beads and nickel chelate (Ni–NTA) 
acceptor beads (8 µL; 25 μg/mL) were incubated for 2 h 
at RT prior to measuring the AlphaScreen signal (Envi-
sion plate reader, PerkinElmer). All dose–response 
graphs (four-parameter logistic curve) and IC50 values 
were obtained using GraphPad Prism 6 software.
Immunoprecipitation
HeLa cells (confluent 10 cm dish) were washed with PBS 
and harvested in 1 mL of Buffer B (10 mM TRIS pH 7.5, 
10 mM KCl, 1 mM CaCl2, 0.1 % Triton X-100). Lysates 
were sonicated, treated with 15 units micrococcal nucle-
ase  (Worthington Biochemical Corporation #LS004798) 
at RT for 10  min. Supernatant was collected following 
centrifugation at 14,000g for 10  min. Immunoprecipi-
tation of FLAG-tagged TRIM24 was performed using 
FLAG M2 antibody conjugated magnetic beads (Sigma 
#M8823). Beads (25 µL) were incubated overnight at 4 °C 
with 2 mg of the whole cell extract. Beads were collected 
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and washed three times with Buffer C (50 mM TRIS pH 
7.5, 1  mM EDTA, 50  mM NaCl, 0.5  % NP40) and two 
times with Buffer D (20  mM TRIS pH 8, 1  mM EDTA, 
150 mM NaCl, 1 % NP40, 1 % Triton X-100, 0.5 % sodium 
deoxycholate). The washed beads were boiled in 2× 
protein loading dye and subjected to SDS-PAGE immu-
noblot analysis using the following antibodies: FLAG-
HRP (Sigma #A8592), H3K23ac (Active Motif #39131), 
H3K4me2 (Active Motif #39141), H3 (Abcam #1791) and 
Lamin B (Santa Cruz #6217). For immunoprecipitation of 
endogenous full-length TRIM24, cell extracts were incu-
bated overnight at 4 °C with 4 μg rabbit IgG or TRIM24 
antibody (Proteintech #14208-1-AP). Protein A Sepha-
rose beads (30 μL; GE Healthcare) equilibrated in buffer 
C were incubated with the extracts for 1 h at 4 °C to pre-
cipitate immune complexes. Beads were washed three 
times with buffer C and two times with buffer D, boiled 
in 2X protein loading dye and subjected to SDS-PAGE 
immunoblot analysis.
AlphaLISA
Hela TRIM24-PB cells were maintained in DMEM 
medium supplemented with 10  % FBS and 5  µg/mL of 
Blasticidin. Cells were seeded (10,000/well, 40 µL) to 
384-well white culture plates (PerkinElmer, #6007680) 
using a Multidrop 384 reagent dispenser (Thermo Sci-
entific) and incubated overnight at 37  °C and 5  % CO2. 
On Day 2, the cells were co-treated with SAHA (10 µM) 
and test compound and incubated at 37 °C and 5 % CO2 
for 2 h. The plates were washed twice with PBS (60 µL at 
RT) using a Biomek FX liquid handler (Beckman Coul-
ter). Lysis buffer (10 µL, Invitrogen #FNN0011), sup-
plemented with protease and phosphatase inhibitors 
(ThermoScientific #1861282), was added to the plate 
using a Multidrop and the plates were sealed and spun 
down, followed by shaking (15 min, 700 rpm at RT) using 
an Eppendorf tabletop mixer. Next, histone extraction 
buffer (10 µL, PerkinElmer #AL009F2) diluted tenfold 
in water was added to all wells, followed by mixing to 
ensure complete extraction. Anti-histone H3 antibody 
(5 µL; 3  nM) diluted in PBS containing 1  % BSA was 
added to each well before the plates were sealed, spun 
down and incubated for 30 min at RT. Anti-FLAG accep-
tor (PerkinElmer #AL112  M) and Streptavidin-donor 
(PerkinElmer, #6760002) beads were diluted and mixed 
together in the Manufacture-provided Detection Buffer 
to generate a 40  µg/mL master suspension. From here, 
10 µL of acceptor and donor bead mixture was added to 
each well, before the plate was sealed and incubated in 
the dark for 2 h at RT. Plates were read on Envision plate 
reader (PerkinElmer) using AlphaScreen protocol and all 
IC50 values (four-parameter logistic curve) were obtained 
using GraphPad Prism 6 software. See Additional file 1: 
Table S2.
In situ cell extraction
OV90 or HeLa cells (20,000 cells/100 µL) were seeded 
into 96-well plates (Corning Costar #3603) using RPMI 
or DMEM medium, respectively, supplemented with 
10  % FBS and grown overnight. Test agents were seri-
ally diluted in DMSO (with or without SAHA) to gener-
ate 10X master compound plates. From here, 11 µL was 
transferred into each well containing 100 µL of growth 
media followed by shaking on a rotation table  (15  min, 
300  rpm at RT) and incubation at 37  °C for 2  h. Plates 
were washed once with PBS (150 µL/well) and then with 
cold, freshly prepared Cytoskeleton (CSK) Buffer (10 mM 
PIPES, 300  mM Sucrose, 100  mM NaCl, 3  mM MgCl2; 
pH  =  6.8). Immediately thereafter, soluble, non-chro-
matin-bound proteins were extracted by addition of cold 
CSK Buffer supplemented with 0.5 % Triton X-100 (150 
µL per well) for 10 min at 4 °C followed by 4 % paraform-
aldehyde fixation (10 min at RT) (Additional file 1: Table 
S3).
Proximity ligation assay (PLA)
Hela cells expressing FLAG-TRIM24-PHD-Bromo-V5 
(TRIM24-PB) (20  K/100 µL) were seeded into 96-well 
plates (Corning Costar #CLS3603) in DMEM media sup-
plemented with 10  % FBS and grown overnight. After 
treatment with SAHA (5  µM, 2  h), plates were washed 
with PBS (150ul per well) and fixed with 4 % paraform-
aldehyde  (10  min  at RT). PLA was performed using 
Duolink® In situ Red Starter Kit Mouse/Goat (Sigma-
Aldrich, DUO92103), according to manufacturer’s rec-
ommendation. Primary antibody pair was: Goat anti-V5 
(1:200 dilution; Bethyl #A190-119A) and Mouse anti-his-
tone H3 (1:4000 dilution; Active Motif, #39763). Follow-
ing PLA, secondary antibody Alexa Fluor®594 Donkey 
Anti-Goat (Invitrogen #A-11056) and Alexa Fluor®488 
Donkey Anti-Mouse (Invitrogen #A-21202) were used 
to measure the total levels of V5 and histone H3. Using 
the High-Content Screening System Operetta with 
40× magnification, cell images from 25 fields in each well 
were taken in 4 channels (Alexa488, Alexa594, Alexa647 
and Hoechst). The image analysis was performed in Har-
mony software by selecting ‘nuclei’ and ‘cytoplasm’ in 
Hoechst channel and ‘dots within nucleus’ in Alexa647 
channel. Gating for single cells of flat morphology was 
done based on nuclei area, roundness and intensity of 
Hoechst in the nucleus and in the cytoplasm. For each 
gated cell, we calculated the mean signal intensity for 
histone H3 (Alexa488 in the nucleus minus Alexa488 in 
the cytoplasm); TRIM24 (Alexa594 in the nucleus minus 
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the Alexa546 intensity in the cytoplasm); and the mean 
number for the PLA signal (number of spots in nucleus). 
For each fluorophore, values were averaged across all the 
gated cells (Additional file 1: Figure S2c).
Immunofluorescence and high‑content image analysis
Standard IF procedures were used. Briefly, cells were per-
meabilized (0.5 % Triton X-100 in PBS) for 15 min and incu-
bated with blocking solution (DAKO #X0909) for 30 min. 
The following primary antibodies were used: goat anti-V5 
(Bethyl #A190-119A) 1:200; mouse anti-FLAG (Sigma 
#F1804) 1:200; rabbit anti-BRD4 (Abcam #ab128874) 1:200; 
rabbit anti-TRIM24 (Proteintech #14208-1-AP) 1:400; rab-
bit anti-K3K23Ac (Cell Signaling #8848) 1:200, and mouse 
anti-histone H3 (Active Motif #39763) 1:4000. Alexa Fluor-
conjugated secondary antibodies were from Invitrogen 
and Hoechst 33342 (Invitrogen, #H3570) was used for 
nuclei counterstaining (10  µg/ml). For each Alexa fluoro-
chrome, images (4–10 fields per well; 20X magnifications) 
were acquired using the Operetta High-Content Screening 
System (PerkinElmer). Image analysis was performed in 
Harmony software (PerkinElmer) by selecting nuclei and 
cytoplasm in Hoechst channel. Gating for single cells of flat 
morphology was done based on nuclei area, roundness and 
intensity of Hoechst in the nucleus and in the cytoplasm. 
In every gated cell, the mean signal intensity value for each 
fluorochrome was calculated separately in nucleus and 
cytoplasm. The specific nuclear signal was estimated sub-
tracting mean cytoplasmic value from nuclear; and average 
value was calculated using at least 1000 cells in each well.
Statistical analysis
For the homogeneous, bead-based AlphaScreen and 
AlphaLISA binding studies dose–response curves are dis-
played as Percent of Control (POC) calculated according 
to the following formula: POC = ([sample signal-average 
background signal]/[average maximum signal −  average 
background signal]) × 100. All EC50 values were calcu-
lated based on these POC values using four-parametric 
nonlinear regression (i.e., curve fitting) software (either 
Genedata Screener™ software version 11 or Graphpad 
Prism 6). For the cell-based AlphaLISA assay, the POC 
values were calculated using the following wells and pro-
cess: (1) a “blank subtraction” was performed by sub-
tracting the mean signal of the blank control wells (which 
contained media but lacked cells) from all of the meas-
ured values; (2) these corrected values were then used 
in the POC formula stated above. The “average back-
ground signal” corresponds to wells that contain cells but 
lacked SAHA treatment while the average “maximum 
signal” corresponds to cells treated with SAHA. For the 
biochemical AlphaScreen assay, the background signal 
corresponds to wells lacking TRIM24 protein and H3 
peptide and the maximum signal is derived from DMSO 
control wells with both the TRIM24 protein and peptide. 
For the in situ cell extraction assay, single cell analysis was 
performed using a grid of 9 non-overlapping rectangular 
fields projected in silico onto the image from each well. 
From these representative fields, at least 1000 cells were 
analyzed per well and each experimental condition was 
represented by at least three independent wells. Average 
and standard Deviation (SD) values were calculated using 
the Harmony software (PerkinElmer). For presentation 
purposes, the data from Harmony were also exported to 
GraphPad Prism and analyzed using the build-in global 
nonlinear regression tool (four-parametric curve fitting) 
to visualize dose–response curves and EC50 values.
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